persmedРоссийский журнал персонализированной медициныRussian Journal for Personalized Medicine2782-38062782-3814ФОНД АЛМАЗОВА10.18705/2782-3806-2022-2-3-6-16persmed-53Research ArticleКОЛОНКА ГЛАВНОГО РЕДАКТОРАEDITORS CORNERБИОМАРКЕРЫ, ИХ ТИПЫ И ОСНОВЫ ПРИМЕНЕНИЯ В ПЕРСОНАЛИЗИРОВАННОЙ МЕДИЦИНЕBIOMARKERS, TYPES AND ROLE IN PERSONALIZED MEDICINEКонрадиА. О.KonradiA. O.

Конради Александра Олеговна, д.м.н., профессор, академик РАН, заместитель генерального директора по  научной работе, заведующий НИО артериальной гипертензии Института сердца и сосудов, заведующий кафедрой организации управления и экономики здравоохранения Института медицинского образования Центра Алмазова

ул. Аккуратова, д. 2, Санкт-Петербург, 197341

Konradi Alexandra O., MD, Dr. Sc., Professor, Academician of the Russian Academy of Science, Deputy General Director for Research, Head of the Research Department of Arterial Hypertension, Head of the Department of Management Organization and Health Economics, Institute of Medical Education

Akkuratova str., 2, Saint Petersburg, 197341

konradi_ao@almazovcentre.ruФедеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени В. А. Алмазова» Министерства здравоохранения Российской Федерации, Научный центр мирового уровня «Центр персонализированной медицины»РоссияAlmazov National Medical Research Centre, World-Class Research Centre for Personalized MedicineRussian Federation20221207202223616Copyright © Конради А.О., 20222022Конради А.О.Konradi A.O.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://persmed.elpub.ru/jour/article/view/53

В обзоре приведены данные о роли биомаркеров в персонализированной медицине. Приведена классификация биомаркеров, описан процесс их валидации и сложности при внедрении в клиническую практику. Кроме того, освещена роль биобанков в появлении новых биомаркеров.

The review summarizes current knowledge about biomarkers in personalized medicine. Classification of biomarkers, the process of validation and challenges in implementation are discussed. The role of biobanks for new biomarkers is also included.

биомаркерперсонализированная медицинапрогнозстратификация рискаbiomarkeroutcomepersonalized medicinerisk stratificationReferencesBiomarkers and Surrogate Endpoints: Preferred Definitions and Conceptual Framework. Clin. Pharmacol. Ther. Mar 2001;69(3): 89–95.Biomarkers and Surrogate Endpoints: Preferred Definitions and Conceptual Framework. Clin. Pharmacol. Ther. Mar 2001;69(3): 89–95.Stratification biomarkers in personalized medicine. Summary report. European Commission, DG Research – Brussels, 10–11 June 2010.Stratification biomarkers in personalized medicine. Summary report. European Commission, DG Research – Brussels, 10–11 June 2010.Morrow DA, de Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation. 2007; 115:949–952.Morrow DA, de Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation. 2007; 115:949–952.Pepe MS, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001; 93: 1054–1061.Pepe MS, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001; 93: 1054–1061.Coupez D, Hulo P, Touchefeu Y, Denis MG, Bennouna J. KRAS mutations in metastatic colorectal cancer: from a de facto ban on anti-EGFR treatment in the past to a potential biomarker for precision medicine. Expert Opin Biol Ther. 2021:1325–1334. DOI:10.1080/14712598.2021.1967318. Epub 2021 Aug 18. PMID:34378483.Coupez D, Hulo P, Touchefeu Y, Denis MG, Bennouna J. KRAS mutations in metastatic colorectal cancer: from a de facto ban on anti-EGFR treatment in the past to a potential biomarker for precision medicine. Expert Opin Biol Ther. 2021:1325–1334. DOI:10.1080/14712598.2021.1967318. Epub 2021 Aug 18. PMID:34378483.Simon R. Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology. Personalized Medicine. 2010, vol. 7, no. 1, pp. 33–47.Simon R. Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology. Personalized Medicine. 2010, vol. 7, no. 1, pp. 33–47.Chau CH, Rixe O, McLeod H, Figg WD. Validation of analytic methods for biomarkers used in drug development. Clinical Cancer Research. 2008, vol. 14, no. 19, pp. 5967–5976.Chau CH, Rixe O, McLeod H, Figg WD. Validation of analytic methods for biomarkers used in drug development. Clinical Cancer Research. 2008, vol. 14, no. 19, pp. 5967–5976.Erickson HS. Measuring molecular biomarkers in epidemiologic studies: laboratory techniques and biospecimen considerations. Statistics in Medicine. 2012, vol. 31, no. 22, pp. 2400–2413.Erickson HS. Measuring molecular biomarkers in epidemiologic studies: laboratory techniques and biospecimen considerations. Statistics in Medicine. 2012, vol. 31, no. 22, pp. 2400–2413.Pencina MJ, D’Agostino Sr RB, D’Agostino Jr RB, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008; 27: 157–172.Pencina MJ, D’Agostino Sr RB, D’Agostino Jr RB, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008; 27: 157–172.Pencina MJ, D’Agostino Sr RB, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011; 30: 11–21.Pencina MJ, D’Agostino Sr RB, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011; 30: 11–21.de Lemos JA, Drazner MH, Omland T, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA. 2010; 304: 2503–12.de Lemos JA, Drazner MH, Omland T, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA. 2010; 304: 2503–12.Di Angelantonio, E, Chowdhury R, Sarwar N, Ray KK, Gobin R, Saleheen D, Thompson A, Gudnason V, Sattar N, Danesh J. B-type natriuretic peptides and cardiovascular risk: Systematic review and metaanalysis of 40 prospective studies. Circulation. 2009; 120, 2177–2187.Di Angelantonio, E, Chowdhury R, Sarwar N, Ray KK, Gobin R, Saleheen D, Thompson A, Gudnason V, Sattar N, Danesh J. B-type natriuretic peptides and cardiovascular risk: Systematic review and metaanalysis of 40 prospective studies. Circulation. 2009; 120, 2177–2187.Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, nodenegative breast cancer. The New England Journal of Medicine. 2004, vol. 351, no. 27, p. 2817–2826.Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, nodenegative breast cancer. The New England Journal of Medicine. 2004, vol. 351, no. 27, p. 2817–2826.Pham MX, Teuteberg JJ, Kfoury AG, et al. Geneexpression profiling for rejection surveillance after cardiac transplantation. The New England Journal of Medicine. 2010, vol. 362, no. 20, p. 1890–1900.Pham MX, Teuteberg JJ, Kfoury AG, et al. Geneexpression profiling for rejection surveillance after cardiac transplantation. The New England Journal of Medicine. 2010, vol. 362, no. 20, p. 1890–1900.Pepe MS, Longton G, Anderson GL, Schummer M. Selecting differentially expressed genes from microarray experiments. Biometrics. 2003, vol. 59, no. 1, pp. 133–142.Pepe MS, Longton G, Anderson GL, Schummer M. Selecting differentially expressed genes from microarray experiments. Biometrics. 2003, vol. 59, no. 1, pp. 133–142.Noma H, Matsui S. Empirical Bayes ranking and selection methods via semiparametric hierarchical mixture models in microarray studies. Statistics in Medicine, 2012.Noma H, Matsui S. Empirical Bayes ranking and selection methods via semiparametric hierarchical mixture models in microarray studies. Statistics in Medicine, 2012.van de Vijver MJ, He YD, van ’t Veer LJ, et al. A geneexpression signature as a predictor of survival in breast cancer. The New England Journal of Medicine. 2002, vol. 347, no. 25, pp. 1999–2009.van de Vijver MJ, He YD, van ’t Veer LJ, et al. A geneexpression signature as a predictor of survival in breast cancer. The New England Journal of Medicine. 2002, vol. 347, no. 25, pp. 1999–2009.Monzon FA, Lyons-Weiler M, Buturovic LJ, et al. Multicenter validation of a 1,550-gene expression profile for identification of tumor tissue of origin. Journal of Clinical Oncology. 2009, vol. 27, no. 15, pp. 2503–2508.Monzon FA, Lyons-Weiler M, Buturovic LJ, et al. Multicenter validation of a 1,550-gene expression profile for identification of tumor tissue of origin. Journal of Clinical Oncology. 2009, vol. 27, no. 15, pp. 2503–2508.Simon R. The use of genomics in clinical trial design. Clinical Cancer Research. 2008, vol. 14, no. 19, pp. 5984–5993.Simon R. The use of genomics in clinical trial design. Clinical Cancer Research. 2008, vol. 14, no. 19, pp. 5984–5993.Cree IA, Kurbacher CM, Lamont A, et al. A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician’s choice in patients with recurrent platinumresistant ovarian cancer. Anti-Cancer Drugs. 2007, vol. 18, no. 9, pp. 1093–1101.Cree IA, Kurbacher CM, Lamont A, et al. A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician’s choice in patients with recurrent platinumresistant ovarian cancer. Anti-Cancer Drugs. 2007, vol. 18, no. 9, pp. 1093–1101.Cobo M, Isla D, Massuti B, et al. Customizing cisplatin based on quantitative excision repair crosscomplementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. Journal of Clinical Oncology. 2007, vol. 25, no. 19, pp. 2747–2754.Cobo M, Isla D, Massuti B, et al. Customizing cisplatin based on quantitative excision repair crosscomplementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. Journal of Clinical Oncology. 2007, vol. 25, no. 19, pp. 2747–2754.Sargent DJ, Conley BA, Allegra C, Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. Journal of Clinical Oncology. 2005, vol. 23, no. 9, pp. 2020– 2027.Sargent DJ, Conley BA, Allegra C, Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. Journal of Clinical Oncology. 2005, vol. 23, no. 9, pp. 2020– 2027.Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2. The New England Journal of Medicine. 2001, vol. 344, no. 11, pp. 783–792.Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2. The New England Journal of Medicine. 2001, vol. 344, no. 11, pp. 783–792.

The authors declare that there are no conflicts of interest present.